| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C25H28NO4S.Mg |
| Molecular Weight | 901.423 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)C([O-])=O.CCO[C@@H](CC4=CC=C(OCCN5C(C)=CC=C5C6=CC=C(SC)C=C6)C=C4)C([O-])=O
InChI
InChIKey=UJYFZCVPOSZDMK-YPPDDXJESA-L
InChI=1S/2C25H29NO4S.Mg/c2*1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20;/h2*5-14,24H,4,15-17H2,1-3H3,(H,27,28);/q;;+2/p-2/t2*24-;/m00./s1
Saroglitazar, a dual peroxisome proliferator-activated receptor PPAR-α/γ agonist, was an emerging therapeutic option on glycemic and lipid parameters. The Zydus Group has launched LipaglynTM ((Saroglitazar) in India for diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In addition, saroglitazar participated in phase II clinical trials that completed enrolment in patients with primary biliary cholangitis and in patients with non-alcoholic steatohepatitis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.65 pM [EC50] | |||
| 3.0 nM [EC50] |
PubMed
ACTIVE MOIETY
SUBSTANCE RECORD
